Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from vTv Therapeutics ( (VTVT) ).
On September 10, 2025, vTv Therapeutics, Inc. will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. This event, available via live audio webcast, highlights the company’s engagement with industry stakeholders and its ongoing efforts to maintain visibility in the healthcare sector.
The most recent analyst rating on (VTVT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.
Spark’s Take on VTVT Stock
According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.
vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.
To see Spark’s full report on VTVT stock, click here.
More about vTv Therapeutics
vTv Therapeutics, Inc. operates in the healthcare industry, focusing on developing therapeutic products.
Average Trading Volume: 5,225
Technical Sentiment Signal: Buy
Current Market Cap: $59.93M
See more insights into VTVT stock on TipRanks’ Stock Analysis page.